| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6024981 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
| US6221392 | UCB INC | Rapidly dissolving robust dosage form |
Apr, 2018
(6 years ago) | |
Kemstro is owned by Ucb Inc.
Kemstro contains Baclofen.
Kemstro has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Kemstro are:
- US6024981
- US6221392
Kemstro was authorised for market use on 30 October, 2003.
Kemstro is available in tablet, orally disintegrating;oral dosage forms.
The generics of Kemstro are possible to be released after 09 April, 2018.
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 30 October, 2003
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
More Information on Dosage
KEMSTRO family patents
